Endometrial Tumor Classification by Histomorphology and Biomarkers in the Nurses’ Health Study

Table 2

Biomarker expression by histotype.

(a) Reportable marker results in 360 tumors studied

	Immunomarker, scored results
	AMACR	ARID1A	HNF1B	ER	GATA3	Napsin A	P16	P53	PAX2	PAX8	PR	PTEN
	POS	NEG	POS	>10%	POS	POS	POS	Mutant	NEG	POS	>10%	NEG
Total cases stained	360	360	360	360	360	360	360	360	360	360	360	360
Total excluded	19	23	19	12	20	16	10	4	13	24	16	52
Total # informative	341	337	341	348	340	344	350	356	347	336	344	308
Total # abnormal	48	115	57	300	16	6	37	37	253	282	264	124
% abnormal	14.1	34.1	16.7	86.2	4.7	1.7	10.6	10.4	72.9	83.9	76.7	40.3

(b) Distribution of reportable marker results, by tumor histotype

Histotype

Immunomarker scored results, informative cases % (/total)

AMACR

ARID1A

HNF1β

ER

GATA3

Napsin A

P16

P53

PAX2

PAX8

PR

PTEN

Endometrioid

13.4% (40/299)

37.2% (110/296)

13.7% (41/299)

92.7% (281/303)

3.3% (10/299)

0% (0/302)

4.2% (13/306)

3.9% (12/311)

75.5% (228/302)

82.7% (243/294)

85.1% (256/301)

43.4% (116/267)

Serous

5.3% (1/19)

5.6% (1/18)

31.6% (6/19)

55% (11/20)

15.8% (3/19)

0% (0/19)

70% (14/20)

73.7% (14/19)

55% (11/20)

95% (19/20)

26.3% (5/19)

11.8% (2/17)

Carcinosarcoma

8.3% (1/12)

16.7% (2/12)

33.3% (4/12)

30.8% (4/13)

16.7% (2/12)

8.3% (1/12)

66.7% (8/12)

35.7% (5/14)

76.9% (10/13)

81.8% (9/11)

15.4% (2/13)

25% (3/12)

Clear cell carcinoma

83.3% (5/6)

0% (0/6)

66.7% (4/6)

33.3% (2/6)

16.7% (1/6)

66.7% (4/6)

0% (0/6)

50% (3/6)

33.3% (2/6)

100% (6/6)

16.7% (1/6)

16.7% (1/6)

Mixed type

20% (1/5)

40% (2/5)

40% (2/5)

33.3% (2/6)

0% (0/4)

20% (1/5)

33.3% (2/6)

50% (3/6)

33.3% (2/6)

100% (5/5)

0% (0/5)

33.3% (2/6)

Percentages are calculated for each marker (columns) by histotype (rows). Scorable results only, noninformative cases excluded.